Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Randomised, Double-blind, Parallel-group, Risperidone-controlled, Fixed-dose Study Evaluating the Safety and Efficacy of Zicronapine in Patients With Schizophrenia

NCT01295372 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT01295372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01295372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Randomised, Double-blind, Parallel-group, Risperidone-controlled, Fixed-dose Study Evaluating the Safety and Efficacy of Zicronapine in Patients With Schizophrenia
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
Not reported
Enrollment
160 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia